Mothers against decapentapentaplegic homolog 1 mRNA (SMAD1 mRNA)

Mothers against decapentapentaplegic homolog 1 (SMAD1) mRNA is the messenger RNA transcript that encodes the SMAD1 protein, a central component of the bone morphogenetic protein (BMP) signaling pathway (UniProt Q15797). The SMAD1 protein acts as a signal transducer and transcription factor; upon activation by BMP receptors, it is phosphorylated and translocates to the nucleus to regulate the expression of genes critical for cell differentiation, proliferation, and development (NCBI Gene 4086). Overexpression or overactivity of SMAD1 is implicated in the progression of various cancers, including prostate and breast cancer, where it facilitates tumor growth and metastasis, as well as in fibrotic diseases and vascular disorders (PubMed 25605100). Targeting SMAD1 mRNA with RNA-based therapeutics, such as small interfering RNAs (siRNAs) or antisense oligonucleotides (ASOs), is an emerging strategy to downregulate SMAD1 protein levels and inhibit pathological BMP signaling. These experimental approaches are designed to provide high specificity in gene silencing, although they face hurdles such as efficient delivery to target tissues and potential off-target effects. Monitoring the levels of SMAD1 mRNA and the phosphorylation status of the SMAD1 protein provides essential biomarkers for assessing the activation state of the BMP pathway and the efficacy of targeted treatments.

Other names

MADH1JV4-1Mad-related protein 1Mothers against DPP homolog 1

RNA interference or antisense-mediated degradation of the mRNA transcript to prevent protein translation.